Latest news for Advance ZincTek (OTC:ADVNF) Stock

Advance ZincTek Ltd is a specialist developer and manufacturer of advanced materials. Its product range suits a wide variety of sunscreens and cosmetics and allows chemists and manufacturers to receive a product tailored to their needs and specifications.

ADVANCE ZINCTEK LTD by ADVANCE ZINCTEK LTD

Advance ZincTek Ltd

<a href="https://www.theinformation.com/articles/logistics-startup-stord-buys-part-of-pitney-bowes-e-commerce-business" title="https://www.theinformation.com/articles/logistics-startup-stord-buys-part-of-pitney-bowes-e-commerce-business">https://www.theinformation.com/articles/logistics-startup-stord-buys-part-of-pitney-bowes-e-commerce-business</a>

'Logistics Startup Stord Buys Part of Pitney Bowes' E-Commerce Business' - The Information

Jones Trading analyst Jason Weaver maintains CTO Realty Growth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTO#NYSE">CTO</a>) with a Buy and raises the price target from $19 to $20.5.

News

Price Target

Analyst Ratings

Jones Trading Maintains Buy on CTO Realty Growth, Raises Price Target to $20.5

WIIM

CGTX

Cognition Therapeutics shares are trading higher after the company announced that it will host an investor presentation to discuss results from its phase 2 SHINE study of CT1812 on Monday July 29, 2024.

Offerings

ENTO

Entero Therapeutics Files For Shelf Of Up To 3.5M Shares Of Common Stock By Selling Stockholders

NYMT

New York Mortgage Trust Files For Mixed Shelf Of Up To $300M

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Increasing Shares Of Common Stock Amount To Sell Under Sales Deal To Offering Price Of Up To $2.6M From Time To Time Through Agent

Macquarie analyst Chad Beynon maintains Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) with a Neutral and lowers the price target from $72 to $68.

Macquarie Maintains Neutral on Boyd Gaming, Lowers Price Target to $68

NDAQ

Nasdaq shares are trading lower after the company announced a secondary offering of 41,604,207 shares of common stock.

Securing prime real estate for cannabis operations is a nuanced endeavor, requiring expertise and a keen understanding of local regulations. Meilad Rafiei, CEO of<a href="https://www.wecannca.com/"> WeCann</a>, a cannabis entitlements, licensing&nbsp;and property brokerage firm, shares insights into this intricate process.
<h2>Priorities In Real Estate For Cannabis</h2>
Rafiei explained that finding the best cannabis property starts with thorough research and a feasibility study to identify cannabis-friendly municipalities.
Digital mapping tools like ArcGIS help highlight viable <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39323795/cannabis-property-funds-control-over-4-5b-are-investors-missing-out-on-high-dividen">properties</a> and create a detailed property database. The next steps involve conducting inspections and negotiating terms with landlords while ensuring compliance with all local regulations.
Thus, finding the right location for <a href="https://www.benzinga.com/cannabis">cannabis operations</a>, whether retail or cultivation, involves thorough research and <a href="https://www.benzinga.com/markets/cannabis/23/11/35662129/are-traditional-cannabis-licensing-models-obsolete-how-reverse-licensing-can-help">strategic planning</a>. &quot;Identifying as many properties as you can that qualify is crucial,&quot; says Rafiei.
For retail, key factors include good frontage, ample parking, and proximity to reputable retail neighbors. &quot;Retailers want good signage and shouldn&#39;t be tucked away in industrial areas,&quot; he adds.
For cultivation, the priorities shift. Being off the beaten path and ensuring robust security measures are essential. However, both retail and cultivation face challenges related to construction costs and timelines.
<h3>The Role Of Digital Tools And Data</h3>
&quot;We create maps that highlight all viable properties within a municipality,&quot; Rafiei explains.
These maps are available via a subscription service, enabling clients to use them independently or with WeCann&#39;s assistance. The maps help identify optimal locations based on zoning, demographics, and the presence of complementary businesses.
Understanding local regulations is another critical aspect. WeCann develops feasibility <a href="https://www.benzinga.com/markets/cannabis/24/06/39390325/up-to-the-minute-market-data-drives-profits-for-cannabis-retailers-investors-heres-how-to-get-in">reports</a> that break down tax implications, operational costs, and timelines for different municipalities.
These reports also include economic factors like demographics and complementary businesses. &quot;If a client wants to be near a 7-Eleven, we can customize the map to highlight those specific businesses,&quot; Rafiei noted.
<h3>Filing Successful Lottery Applications</h3>
Winning a lottery for a cannabis license involves more than just luck. Rafiei stresses the importance of thorough preparation and understanding of the local political agenda.
&quot;We&#39;ve submitted about 200 licensing applications across nearly 60 <a href="https://www.benzinga.com/markets/cannabis/24/03/37546590/city-owned-cannabis-dispensaries-minnesota-says-yes-may-soon-open-first-government-run-weed-shop">municipalities</a>. We&#39;ve experienced a little bit of everything when it comes to politics and regulations,&quot; he noted.
&quot;You need a strong business plan and an operational work plan,&quot; he advises. Community benefit plans that genuinely address local needs can also significantly enhance an application&#39;s chances of success.
Once a company secures a property and state approval, navigating municipal requirements becomes the next hurdle.
&quot;<a href="https://www.benzinga.com/markets/cannabis/24/06/39368184/too-many-cannabis-shops-too-small-profit-how-to-play-the-municipal-game-in-the-legal-weed-era">Municipalities often demand </a>a detailed business plan, including operational workflows,&quot; explained Rafiei. Additionally, municipalities frequently request a community benefit plan, especially in competitive licensing scenarios.
Read Also:&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39866180/this-cannabis-lender-is-sitting-on-a-stack-of-capital-100-dividends-meet-equity-lik">This Cannabis Lender Is Sitting On A Stack Of Capital: 100% Dividends Meet Equity-Like Returns</a>
<h3>Check For Good Bones</h3>
Converting properties for cannabis use presents unique challenges. &quot;It&#39;s usually better to find existing<a href="https://www.benzinga.com/news/24/07/39564006/holding-onto-outdated-growing-methods-commercial-growers-explains-what-it-takes-to-outpace-the-marke"> buildings </a>rather than starting from scratch,&quot; Rafiei says, citing post-COVID construction delays and increased costs.
Yet, properties with deferred maintenance can be problematic, underscoring the need for detailed inspections. For example, securing adequate power is a significant challenge in cannabis real estate.
&quot;Property owners might claim they have 12000 amps, but you can&#39;t just take their word for it,&quot; Rafiei explained. Misjudgments can take up to 18 months. &quot;It&#39;s crucial to double-check how power is split and delivered to avoid unforeseen issues,&quot; he added.
<h3>All About The Legwork</h3>
Securing cannabis real estate involves significant legwork, starting with cold-calling property owners who may know little about the cannabis industry. &quot;Winning them over is part of the game,&quot; Rafiei explains.
Building credibility often begins with educating property owners about <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38114174/how-to-secure-dividends-and-returns-in-marijuana-real-estate-analysis-reveals-stock">market trends</a>.
Understanding local dynamics is also crucial. Rather than delving into the historical context of cannabis, Rafiei focuses on <a href="https://www.benzinga.com/markets/cannabis/24/07/39946113/gop-attor-ney-gen-er-al-in-texas-loses-legal-battle-against-towns-with-decriminalized-cannabis-i">current events and regulations</a> in the property owner&#39;s city and state. &quot;Once they realize their city council and mayor support cannabis businesses, it eases their concerns,&quot; he notes.
These markets require navigating <a href="https://www.benzinga.com/markets/cannabis/24/01/36880346/new-zoning-regulations-floridas-cannabis-donors">evolving regulations</a> and building local relationships. Establishing a connection through relevant, localized information helps build trust. Financial discussions are also inevitable in this process. Rafiei stresses the importance of clear communication about potential<a href="https://www.benzinga.com/markets/cannabis/24/05/38585616/this-real-estate-company-just-poured-8-5m-into-a-new-york-based-cannabis-operation"> earnings and risks</a>.
&quot;Property owners take on additional risks with cannabis tenants due to federal laws,&quot; he says. Addressing these concerns, while highlighting the financial benefits such as increased foot traffic for surrounding businesses, is essential. &quot;Cannabis tenants can positively impact nearby retailers,&quot; he adds, underscoring the broader economic advantages of retail cannabis.
<h3>The Full-Time Job Of Finding Cannabis Properties</h3>
Rafiei highlights that finding the right property for cannabis operations is a full-time job.
&quot;You can&#39;t just do this part-time; it requires dedicated effort,&quot; he asserts. Engaging a firm like WeCann, with specialized knowledge and resources, can be costly upfront but saves significant time and money in the long run.
As Rafiei sums it up, &quot;Time kills deals. Having the right team can make all the difference.&quot;
Read Next:&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39392754/brick-and-mortar-investments-build-cash-flow-and-11-price-uptick-for-this-cannabis-">Brick-And-Mortar Investments Build Cash Flow And 11% Price Uptick For This Cannabis Stock</a>
These issues will be among the hot topics at the upcoming Benzinga Cannabis Capital Conference in Chicago this Oct. 8-9. Join us to get more insight into what the wave of weed legalization means for the future of investing in the&nbsp;industry. Hear directly from top executives, investors, advocates, and policymakers.&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noreferrer noopener" target="_blank">Get your tickets now</a>&nbsp;before prices go up by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noreferrer noopener" target="_blank">this link</a>.
Photo: AI-generated image.&nbsp;

Cannabis

Emerging Markets

Entrepreneurship

Contracts

Asset Sales

Legal

Management

Exclusives

Markets

Interview

General

Real Estate

Ultimate Guide To Winning The Cannabis Lottery: Real Estate Secrets For Finding The Perfect Property

Investors with a lot of money to spend have taken a bearish stance on Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with KO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Coca-Cola.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 50%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $318,061, and 5 are calls, for a total amount of $168,302.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $52.5 to $70.0 for Coca-Cola over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Coca-Cola's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Coca-Cola's significant trades, within a strike price range of $52.5 to $70.0, over the past month.
<h3>Coca-Cola Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722024954_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>KO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$2.25</td>
<td>$1.99</td>
<td>$2.19</td>
<td>$69.00</td>
<td>$109.5K</td>
<td>8</td>
<td>500</td>
</tr>
<tr>
<td>KO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$0.24</td>
<td>$0.23</td>
<td>$0.24</td>
<td>$65.00</td>
<td>$65.9K</td>
<td>5.5K</td>
<td>3.7K</td>
</tr>
<tr>
<td>KO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$2.11</td>
<td>$2.01</td>
<td>$2.08</td>
<td>$69.00</td>
<td>$62.4K</td>
<td>8</td>
<td>500</td>
</tr>
<tr>
<td>KO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.35</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$65.00</td>
<td>$44.2K</td>
<td>10.0K</td>
<td>285</td>
</tr>
<tr>
<td>KO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$2.14</td>
<td>$2.05</td>
<td>$2.07</td>
<td>$69.00</td>
<td>$41.3K</td>
<td>8</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About Coca-Cola</h3>
Founded in 1886, Atlanta-headquartered Coca-Cola is the world's largest nonalcoholic beverage company, with a strong portfolio of 200 brands covering key categories including carbonated soft drinks, water, sports, energy, juice, and coffee. Together with bottlers and distribution partners, the company sells finished beverage products bearing Coca-Cola and licensed brands through retailers and food-service locations in more than 200 countries and regions globally. Coca-Cola generates around two thirds of its total revenue overseas, with a significant portion from emerging economies in Latin America and Asia-Pacific.
Having examined the options trading patterns of Coca-Cola, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Coca-Cola's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 13,317,693, the KO's price is up by 1.48%, now at $67.05. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>What The Experts Say On Coca-Cola</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $72.0.
<ul>
<li>An analyst from JP Morgan has decided to maintain their Overweight rating on Coca-Cola, which currently sits at a price target of $72. </li>
<li>Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Coca-Cola, targeting a price of $75. </li>
<li>An analyst from Barclays persists with their Overweight rating on Coca-Cola, maintaining a target price of $70. </li>
<li>An analyst from Wells Fargo has decided to maintain their Overweight rating on Coca-Cola, which currently sits at a price target of $73. </li>
<li>Maintaining their stance, an analyst from TD Cowen continues to hold a Hold rating for Coca-Cola, targeting a price of $70. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Coca-Cola with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Check Out What Whales Are Doing With Coca-Cola

Whales with a lot of money to spend have taken a noticeably bearish stance on Morgan Stanley.
Looking at options history for Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) we detected 19 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 47% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $509,400 and 15, calls, for a total amount of $1,000,027.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $110.0 for Morgan Stanley over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Morgan Stanley's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Morgan Stanley's substantial trades, within a strike price spectrum from $55.0 to $110.0 over the preceding 30 days.
<h3>Morgan Stanley Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722024949_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.15</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$105.00</td>
<td>$320.8K</td>
<td>4.0K</td>
<td style="text-align: right;">649</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.4</td>
<td>$5.15</td>
<td>$5.35</td>
<td>$95.00</td>
<td>$267.5K</td>
<td>4.5K</td>
<td style="text-align: right;">500</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$5.8</td>
<td>$5.7</td>
<td>$5.75</td>
<td>$105.00</td>
<td>$144.9K</td>
<td>603</td>
<td style="text-align: right;">253</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$6.0</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$105.00</td>
<td>$132.0K</td>
<td>4.0K</td>
<td style="text-align: right;">980</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$4.45</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$105.00</td>
<td>$70.4K</td>
<td>1.7K</td>
<td style="text-align: right;">162</td>
</tr>
</tbody>
</table>

<h3>About Morgan Stanley</h3>
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.
Having examined the options trading patterns of Morgan Stanley, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Morgan Stanley</h3>
<ul>
<li>Trading volume stands at 5,900,307, with MS's price up by 0.61%, positioned at $104.19.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 82 days.</li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Morgan Stanley with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Morgan Stanley Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Abbott Laboratories.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 46%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $275,511, and 9 are calls, for a total amount of $475,413.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $130.0 for Abbott Laboratories over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Abbott Laboratories's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Abbott Laboratories's whale activity within a strike price range from $85.0 to $130.0 in the last 30 days. 
<h3>Abbott Laboratories 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722024944_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.4</td>
<td>$5.95</td>
<td>$6.25</td>
<td>$125.00</td>
<td>$124.9K</td>
<td>479</td>
<td style="text-align: right;">204</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.8</td>
<td>$8.6</td>
<td>$8.8</td>
<td>$105.00</td>
<td>$88.1K</td>
<td>1.1K</td>
<td style="text-align: right;">9</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$1.39</td>
<td>$1.38</td>
<td>$1.38</td>
<td>$105.00</td>
<td>$68.8K</td>
<td>371</td>
<td style="text-align: right;">532</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$18.9</td>
<td>$16.65</td>
<td>$18.53</td>
<td>$125.00</td>
<td>$50.0K</td>
<td>0</td>
<td style="text-align: right;">33</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$24.15</td>
<td>$23.7</td>
<td>$23.78</td>
<td>$85.00</td>
<td>$47.5K</td>
<td>2.9K</td>
<td style="text-align: right;">85</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
In light of the recent options history for Abbott Laboratories, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Abbott Laboratories</h3>
<ul>
<li>Currently trading with a volume of 5,720,670, the ABT's price is down by -0.67%, now at $105.25. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 82 days.</li>
</ul>
<h3>Expert Opinions on Abbott Laboratories</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $120.0.
<ul>
<li>Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Abbott Laboratories, targeting a price of $120. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abbott Laboratories with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Abbott Laboratories's Options Frenzy: What You Need to Know

When Drew Bledsoe left Washington State University, he joined one of the highest elections in sports: number one overall <a href="https://www.benzinga.com/topic/nfl?page=11">NFL draft pick</a>. 
A few years later, Bledsoe found himself in a position he never thought he'd be in as a backup to Tom Brady. Bledsoe shared his journey and rollercoaster experience in the NFL with Benzinga founder Jason Raznick in a <a href="https://www.youtube.com/watch?v=I2gzfyNvhBQ&amp;t=11s">recent episode of The Raz Report podcast</a>. Bledsoe, who now owns and operates three wineries in his home state of Washington, spoke candidly about the challenges he overcame as a football player and how that has shaped the rest of his life and now business career. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="#75 NFL Star Drew Bledsoe Talks Adversity, Business, and Wine" width="500" height="281" src="https://www.youtube.com/embed/I2gzfyNvhBQ?start=11&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Quoted: "It's life, right?" Bledsoe said. "In life shit's going to come your way, positive or negative, you can't control what's coming at you, you can control what you do with it. That's the deal with me, I tried to handle it the right way at each juncture to the best that I could and because of that I ended up with a great relationship with all of the cities I played in and great relationships with all these teammates." Bledsoe was the starting quarterback for the New England Patriots for eight seasons before an injury sidelined him, leaving the door open for Brady to take over. Before the 2001 season, Bledsoe signed a then-record $103 million contract for 10 years with the Patriots. Set Backs: But, just two games into the season, Bledsoe was injured on a hit by New York Jets linebacker Mo Lewis that sheared a blood vessel in Bledsoe's chest, causing a hemothorax that led to rapid blood internal blood loss. If the trainers hadn't caught the injury soon after the conclusion of the game, Bledsoe's life could have been in danger. Brady stepped in for Bledsoe and ended up taking the Patriots to the playoffs where the team would eventually win the Super Bowl. Bledsoe, who stepped in for an injured Brady during the AFC Championship game, spoke about the difficulties of being sidelined for the Super Bowl. "To have a chance to come in and play in that game [AFC Championship] was great," Bledsoe said. "The thing that really sucked about it though, was I came in and played, we won, then we're going to the Super Bowl then Tommy's back in for the Super Bowl. I was like man this is bullshit, it's like you're giving a starving man a snack. You get to go play a little bit, then you get to the ultimate game and no dice." Second Chances: After that season, the Patriots traded Bledsoe to their division rival the Buffalo Bills, giving Bledsoe a chance to rebuild his career following the injury-shortened season. Bledsoe threw for more than 4,000 yards in the 2002 season and earned a trip to the Pro Bowl, the NFL's All-Star Game. Bledsoe went on to play for the Dallas Cowboys before retiring in 2006. Since then, Bledsoe moved back to Walla Walla, Washington, his hometown and began a new career that comes with a significantly reduced likelihood of serious injury: winemaking. Bledsoe teamed up with Josh McDaniels (not the NFL coach), who is also from Walla Walla, and has founded three wineries in the region: Bledsoe McDaniels Winery, Doubleback and the Bledsoe Family Winery. Bledsoe realized while playing football that his small hometown of Walla Walla was producing some of his favorite wines, which led to his passion for winemaking. <a href="https://www.youtube.com/watch?v=I2gzfyNvhBQ&amp;t=11s">Watch the full interview with Bledsoe here. </a>

From Number One Draft Pick To Benched: Drew Bledsoe On Overcoming Adversity, Roasting Tom Brady And More

Dreaming of a comfortable retirement is something most Americans share. But how much cash do you need to make those golden years truly golden? According to a recent survey by Northwestern Mutual, the average person <a href="https://www.benzinga.com/personal-finance/24/07/39892121/top-economist-debunks-myth-you-need-1-46-million-to-retire-argues-you-can-retire-comfortably-wit?comments_open=true">thinks they&#8217;ll need $1.46 million</a>. That&#8217;s a pretty hefty goal post! While a million bucks has long been the retirement savings target, the truth is that many people are starting from scratch. But what about those who&#8217;ve saved a substantial chunk of change? Let&#8217;s talk about the $500,000 club.
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
</ul>
Believe it or not, according to the 2022 Survey of Consumer Finances, only 9% of American households have saved half a million dollars or more for retirement. That&#8217;s right, less than one in 10 families has reached this milestone. It&#8217;s an impressive feat, but it also highlights the challenges many people face.
<ul>
<li>According to the survey results, 46% of households have some type of retirement savings. </li>
<li>26% reported having $100,000 or more in their nest eggs. </li>
</ul>
See Also: How much money will a $200,000 annuity pay out each month?<a href="https://www.benzinga.com/money/200k-annuities-adv"> The numbers may shock you.</a>
Saving $500,000 might sound like a lot of money, but will it fund a comfortable retirement? The popular 4% rule suggests you can withdraw 4% of your savings annually without depleting your nest egg. For a $500,000 nest egg, that&#8217;s $20,000 a year. Sure, it might cover some expenses, but it&#8217;s unlikely to maintain your preretirement lifestyle for many people.
Luckily, there&#8217;s more to the retirement income picture than just savings. <a href="https://www.benzinga.com/personal-finance/24/05/38943129/social-security-fears-go-viral-should-you-claim-early-like-dave-ramsey-says">Social Security benefits</a> can provide a steady income stream, and part-time work or rental properties can supplement your retirement funds. The average Social Security benefit is around $1,827 per month, up to about $22,000 a year. Combine that with the $20,000 from your savings, and you&#8217;re looking at roughly $42,000 annually. This can help cover basic living expenses, but it might still be tight for some.
Trending: This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a>
Interestingly, according to a Go Banking Rates survey, nearly 40% of Americans think they can retire comfortably on $500,000 or less. While it&#8217;s possible for some, having a realistic retirement plan is important. If you aim<a href="https://www.benzinga.com/personal-finance/24/05/39069576/are-you-rich-heres-the-net-worth-you-need-to-be-poor-middle-class-and-wealthy"> for a more lavish lifestyle</a>, you&#8217;ll probably need to save more.
Whether you&#8217;re just starting your savings journey or well on your way to $500,000, every dollar counts. Contributing regularly to retirement accounts, taking advantage of employer matches, and exploring other investment options can make a big difference.
And for those who&#8217;ve already reached the half-million-dollar milestone, congratulations! You&#8217;re in elite company. But remember, retirement is a long haul. Keep saving, investing wisely, and planning for the future.
The bottom line? Saving for retirement takes time and discipline. Understanding your financial goals and taking proactive steps can increase your chances of enjoying a comfortable retirement.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a></li>
</ul>

Personal Finance

Can You Guess What Percent Of People Have $500,000 Saved For Retirement? Shockingly, It's Probably Less Than You Think

<a href="https://www.globenewswire.com/Tracker?data=XNyVZKk25f1gyNB7hzmTSdHaaHzJe0rJB-sZrPcXfoSZjxAPg_WzB1XwAy_4S60SNmRfxO90iLjgwroG9Y3NO76ivoXx0ZoElwrFswa77rI=">Cognition Therapeutics, Inc.</a> (the "Company" or "Cognition") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024 at 8:30a.m. ET to discuss the clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 "SHINE" study. SHINE enrolled 153 adults with mild-to-moderate Alzheimer's disease who were randomized to receive once-daily oral doses of CT1812 (100mg or 300mg) or placebo for six months. The only way to participate in the live webcast is to register online by <a href="https://www.globenewswire.com/Tracker?data=GDOb9ohcKurk8mNKJIYcLSKviZMpMLgjoixA9TjLwMqcqi1KDuCo_tA7OlIDpNt4bdhwGVuaegRq7bXzvIMVI-FXMzDUWFJfSOtV8F8Z1Qhv1CSFFlGZU5Vjkahv_k0A">clicking here</a>. The event will also be archived on the Investor Relations section of the Cognition website. &nbsp;
Clinical findings from the SHINE study, including safety and cognitive and functional endpoints will be described in a poster presentation on Monday, July 29 in person at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, 2024. Biomarker and proteomic analyses from SHINE participants who provided cerebrospinal fluid (CSF) samples will also be reported on Monday.
In addition, results of a meta-analysis of phosphoproteomics from the 23-patient SPARC study and the first 24 SHINE participants (SHINE-A) will be presented on Sunday, July 28. Results of proteomic analyses from this meta-analysis were recently accepted for publication in Alzheimer's &amp; Dementia, the Journal of the Alzheimer's Association.

Biotech

Cognition Therapeutics Hosts Investor Webcast To Discuss Results From Phase 2 SHINE Study Of CT1812 In Mild-to-Moderate Alzheimer's Disease At 8:30am ET On Monday July 29, 2024

ZCAR

Zoomcar Holdings Got Notice From Nasdaq Notifying The Co Was Not In Compliance With Nasdaq Listing Rule 5450(b)(2)(c)

Macquarie analyst Chad Beynon maintains Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) with a Outperform and raises the price target from $154 to $162.

CHDN

Macquarie Maintains Outperform on Churchill Downs, Raises Price Target to $162

The tech earnings season started with disappointments for investors as shares of the <a href="https://www.benzinga.com/topic/magnificent-seven">Magnificent Seven companies</a> all declined during the trading week.
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) reported stronger-than-expected earnings and revenue, but missed analysts&#8217; targets on <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39925881/alphabet-investors-fret-over-margin-impact-of-higher-ai-related-capex-but-fund-mana">YouTube advertising revenue</a>, leading to the worst week of the year for the Google parent company's stock.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) missed <a href="https://www.benzinga.com/news/earnings/24/07/39918390/tesla-q2-earnings-highlights-revenue-beat-eps-miss-robotaxi-update-2024-growth-rate-to-be-notably-l">quarterly earnings forecasts</a> due to thinner profit margins impacted by lower vehicle prices and restructuring charges. The electric-vehicle giant also postponed the announcement of the Robotaxi to October. Shares fell 12.3% in reaction to the earnings report on Wednesday, marking the worst one-day performance since September 2020.
The tech-heavy Nasdaq 100 index notched the second-straight week in the red for the first time since April.
Among mega-cap stocks, Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) experienced the largest declines this week, followed by General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) , <a href="https://www.benzinga.com/news/24/07/39968735/gm-shares-fall-amid-earnings-report-and-sympathy-drop-with-ford">amid disappointing earnings reports</a>. The top performers among mega caps were 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), buoyed by surprising results.
Small-cap stocks outperformed once again this week, with the Russell 2000 Index marking its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39992214/russell-2000-notches-third-week-of-gains-strongest-streak-since-august-2022-small-c">third straight week of gains</a>, supported by high expectations for upcoming interest rate cuts.
On the macroeconomic front, the U.S. economy grew at an annualized pace of 2.8% in the second quarter, accelerating from the first quarter and topping expectations <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39957034/us-economy-expands-2-8-in-q2-tops-estimates-weekly-jobless-claim-fall">of 2% growth</a>.
Chart Of The Week: US GDP Growth Doubled From Q1 To Q2 2024
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52-1024x458.png" alt="" class="wp-image-460108" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52-1024x458.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52-300x134.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52-768x344.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52-1536x687.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
You might have missed…
Inflation Gauge Falls: An inflation measure followed by the Federal Reserve fell to 2.5% in June, hitting the lowest levels since February 2021 and cementing market expectations of a rate cut in September.
Yet the Fed is seeking a more &#8220;durable downward trend&#8221; before <a href="https://www.benzinga.com/top-stories/24/07/39987142/feds-favorite-inflation-gauge-keeps-falling-but-fed-wants-durable-downward-trend-economist-says">deciding to cut rates,</a> according to a Comerica Bank economist.
Alphabet Shares Drop: OpenAI plans to launch SearchGPT, a tool aimed at challenging Google&#8217;s search dominance, opening a 10,000-person waiting list to <a href="https://www.benzinga.com/news/24/07/39968522/alphabet-stock-falls-as-openai-plans-searchgpt-what-investors-need-to-know">test the new product.</a>
Mortgage Rates Ease: Mortgage rates have declined to the lowest levels since February, with the average 30-year fixed interest rate falling to 6.62%, driven by investor anticipation of future interest rate cuts. Despite this, demand <a href="https://www.benzinga.com/news/large-cap/24/07/39931211/mortgage-rates-hit-lowest-point-since-february-as-investors-anticipate-fed-rate-cuts">among homebuyers remains weak</a>.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39970069/investors-go-all-in-on-small-caps-pour-over-6-billion-into-russell-2000-etf-this-month-they-will">Investors Go All In On Small Caps, Pour Over $6 Billion Into Russell 2000 ETF This Month: They &#8216;Will Return To Larger-Cap Alternatives,&#8217; Veteran Analyst Says</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Large Cap

Macro Economic Events

Mid Cap

Sector ETFs

Eurozone

Commodities

Small Cap

Econ #s

Economics

Federal Reserve

Tech

ETFs

GOOGL

TSLA

Tech Stocks Slide On Earnings, US Economy Flexes Muscles, Small-Cap Rally Continues: This Week In The Markets

Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) (the "Company" or "Nasdaq") today announced a secondary public offering of 41,604,207 shares of its common stock currently held by Argus Seller, LP (the "Selling Stockholder"), an affiliate of certain funds managed by Thoma Bravo, L.P. Nasdaq is not selling any shares of its common stock and will not receive any proceeds from the sale of the shares by the Selling Stockholder in the offering. &nbsp;
In addition, on July 25, 2024, Nasdaq entered into a share repurchase agreement with the Selling Stockholder conditioned on the secondary public offering, pursuant to which Nasdaq has agreed to purchase from the Selling Stockholder 1,200,000 shares of common stock, provided that the total amount of shares to be repurchased does not exceed $120 million (the "Concurrent Share Repurchase"). The Concurrent Share Repurchase is part of the Company's existing share repurchase program and offsets employee dilution. Nasdaq intends to fund the Concurrent Share Repurchase from existing cash on hand, together with borrowings under its commercial paper program. The underwriters will not receive any compensation for the shares being repurchased by Nasdaq.
At the completion of the offering and the Concurrent Share Repurchase, the Selling Stockholder is expected to hold 42,804,207 shares, representing approximately 7.4% of Nasdaq's outstanding shares, which remain subject to an existing contractual lock-up until May 1, 2025.&nbsp;&nbsp;
Goldman Sachs &amp; Co. LLC is acting as sole book-running manager for the offering.

Nasdaq Announces Launch Of Secondary Offering Of 41,604,207 Shares Of Its Common Stock Currently Held By Argus Seller, LP; In Addition, Entered Into A Share Repurchase Agreement With The Selling Stockholder Conditioned On The Secondary Public Offering, Pursuant To Which Nasdaq Has Agreed To Purchase From The Selling Stockholder 1.2M Shares Of Common Stock, Provided That The Total Amount Of Shares To Be Repurchased Does Not Exceed $120M

Rail Vision Ltd. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSN#NASDAQ">RVSN</a>), a technology company at the forefront of revolutionizing railway safety and the data-related market, announced today that on July 22, 2024, the Company received a written notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its Ordinary Shares was below $1.00 per share for the last 30 consecutive business days.

RVSN

Rail Vision Receives Nasdaq Notification Regarding Minimum Bid Requirements

Advance ZincTek

-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- 
&nbsp;

-- Multiple production suites with total capacity of 4000L, with further expansion opportunities --

-- Adverum to invest over&nbsp;$80M&nbsp;to be production-ready by end of 2023 and create more than 200 life sciences jobs; Company to receive state and local incentives of up to&nbsp;$9M&nbsp;--

REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="/stock/ADVM#NASDAQ">ADVM</a>), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced plans for a new Good Manufacturing Practices facility in Durham, North Carolina. Adverum will invest over&nbsp;$80 million&nbsp;in the 174,000-square-foot facility, located in Research Triangle Park (RTP). The site will include four 1,000-liter bioreactors, with space for future expansion and will create more than 200 jobs.

&quot;We are building a team with exceptional AAV-gene therapy experience and we are thrilled to join the highly-skilled and diverse North Carolina biotech community,&quot; said&nbsp;<a href="https://www.globenewswire.com/Tracker?data=wKZkNisky8HWzjBS99xo9NsdDCnMUiepbT_zJDIjxMfHr4dNLgbHO0s5fU5gqdpB-DXCKHewjDjYKSL_vrJ3zWjvg8oiBUdopzkMdpeUzSM=" target="_blank">Laurent Fischer, M</a><a href="https://www.globenewswire.com/Tracker?data=3g6ma3NImNKrvZ96yEJigcr9bS_eadxDKZI03ldr3MxhXhMO0CTadPbPYA-vjY17jnkId0pWJAnEO5H9cZiuaw==" target="_blank">.</a><a href="https://www.globenewswire.com/Tracker?data=S1VcaKIt_vf1R2HrrjflOrPdzrUweV3P-gPm79weMo6FLWqzq6bt0nkWQgth2TuM3j8MmYmRusQy9wuWAa1_Uw==" target="_blank">D</a><a href="https://www.globenewswire.com/Tracker?data=Sq1_9-hoJktEgN4coJ-4YV0AhoxrXd6gfIMghz_SjduLv7O-m-9CmLEMj9-c0p6Ji_kukYp84JxC7ufsmMMrxA==" target="_blank">.</a><a href="https://www.globenewswire.com/Tracker?data=mUzCDy-_ZGRRTgsKMmOOmTBECm0FFIfLOX21y9cJXf5m2YItJ41YHXbc-imb4mM6IHwyo4ccgKhLIkPhpmcR3A==" target="_blank">,&nbsp;</a><a href="https://www.globenewswire.com/Tracker?data=APl8y_DXHq5UP_BtiTMbkbgPOOdd3dFZQjMgVdhnYI_TNouUTRARW7GxkKOl-WJ0NalTYQX1WIcRwDtRi-DinA==" target="_blank">c</a><a href="https://www.globenewswire.com/Tracker?data=xOX6VZeviZ44EUuDjewMlnuk_swLWI94w1ZIQSmBCiOh3rmTyi5-Vf2c_3RX02KCUHmpr90QsjJp7OZQEN5eQA==" target="_blank">hief&nbsp;</a><a href="https://www.globenewswire.com/Tracker?data=Fw05YHPqqnEnEg9laRa5-uhPR-4_ktqfAIAcr8NINvQKRCShN30gPpuFGGSHyzCAyudqkLSxASe0hdWeLnt-Kg==" target="_blank">e</a><a href="https://www.globenewswire.com/Tracker?data=kLGbIsxrO57gs9tNJqnqnqKTep2nbmH277mFElMLOhem1Qea3bfHqCd2Ek94nPA7HDWDvQmPCuYLpv4P5mzeng==" target="_blank">xecutive&nbsp;</a><a href="https://www.globenewswire.com/Tracker?data=56RsqHRz7naEdZcQmvuOaDZ6jxwYuEmaPcBsc38EnzzgV22Lm3m-UmEijXo4co7sdRbHaxXKT29Gh_aBvrn4Kw==" target="_blank">o</a><a href="https://www.globenewswire.com/Tracker?data=fsKgg7rQ6lN_syT7hZeSxUGPUqW5zckQWxjH17jcuLNjvhIdTDiB6TEqFHW9z9HND0dc_M3W7UML9BhvaifP6DnVCHGFQekxO4VbrPnj62OXJhz-_E1zVAM16hUg28ox" target="_blank">fficer at Adverum Biotechnologies</a>. &quot;This state-of-the-art facility will support our commercialization of ADVM-022, the potential first mass marketed gene therapy for wet AMD and DME.&quot;

&quot;Our new in-house commercial manufacturing facility sets the foundation of our overall manufacturing strategy,&quot; said&nbsp;<a href="https://www.globenewswire.com/Tracker?data=E8O42mrB0djXfJIGVkifzzGffzbn7_Ii7DZ0LuRhltQu3lWwJbgoHQdX--JGMDB2Sxi1QaRVJhDrk6kbYMRCSMkm98U2F3NKU11kPw9XPEuc-FIb2ZCGZ6htSzlUlJwetu0s6ghpo4EcZbG50n2b7aqJaUjdkD-FiMwRG97KVhw=" target="_blank">Angela Thedinga, chief technology officer at Adverum</a>. &quot;Our new site will provide dedicated commercial supply, while we continue to leverage CMO partnerships for flexible clinical and additional commercial supply. This&nbsp;multi-source strategy capitalizes on our internal AAV manufacturing expertise while providing both security and flexibility as we prepare to deliver one of the first gene therapies for large indications.&quot;

Adverum will be receiving up to&nbsp;$9 million&nbsp;in state and local incentives as it expands into North Carolina, including a Job Development Investment Grant (JDIG), which will provide up to&nbsp;$3 million&nbsp;in funding over 12 years and was approved by the state&#39;s Economic Investment Committee today. Additionally, Adverum will receive a training grant of over&nbsp;$400,000&nbsp;and an estimated&nbsp;$6 million&nbsp;from local and other incentives.

&quot;Our state&#39;s dynamic workforce continues to propel life-changing innovation and keeps North Carolina at the forefront of biomanufacturing through life sciences companies like Adverum,&quot; said Governor Roy Cooper.

Multiple organizations were instrumental in facilitating Adverum&#39;s entry into North Carolina, including North Carolina Department of Commerce, Economic Development Partnership of North Carolina, North Carolina General Assembly, Durham County, Greater Durham Chamber of Commerce, North Carolina Community College System, North Carolina Biotechnology Center, and Duke Energy.

About Adverum Biotechnologies 
 
Adverum Biotechnologies (NASDAQ:<a class="ticker" href="/stock/ADVM#NASDAQ">ADVM</a>) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit&nbsp;<a href="https://pro.benzinga.com/dashboard/www.adverum.com">www.adverum.com</a>.

Forward-Looking Statements 
 
Statements contained in this press release regarding the events or results that may occur in the future are &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding: the amount that Adverum expects to invest in the manufacturing facility; the benefits that Adverum expects to receive from the manufacturing facility; and the amounts that Adverum expects to receive in state and local incentives. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include risks inherent to, without limitation: unexpected delays in completion of moving into and finishing the build out of the manufacturing facility; Adverum&#39;s novel technology, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; and the effects of the COVID-19 pandemic on the company&#39;s operations and on the company&#39;s ongoing clinical trials. Risks and uncertainties facing Adverum are described more fully in Adverum&#39;s Form 10-Q filed with the&nbsp;SEC&nbsp;on&nbsp;November 5, 2020&nbsp;under the heading &quot;Risk Factors.&quot; All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

<img src="https://www.globenewswire.com/newsroom/ti?nf=ODEyMjMwOCMzOTA4MzIzIzIwMDYyMTI=" style="height:1px; width:1px" /> 
&nbsp;

<pre>
Investor Relations Contact
Myesha Lacy
Vice President, Investor Relations and Corporate Communications
Adverum Biotechnologies, Inc.
T: 650-649-1257
E: <a href="mailto:mlacy@adverum.com">mlacy@adverum.com</a>

Media Contact
Andrea Cohen
Sam Brown Inc. 
T: 917-209-7163
E: andreacohen@sambrown.com</pre>

<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/f3cb280c-2b19-4dae-b780-567fdba991a4"><img alt="Primary Logo" src="https://ml.globenewswire.com/media/f3cb280c-2b19-4dae-b780-567fdba991a4/small/logo-jpg.jpg" style="height:32px; width:150px" /></a>

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Advance ZincTek

News

Latest news for Advance ZincTek (OTC:ADVNF) Stock

Thursday, January 07, 2021